New insight into daptomycin bioavailability and localization in
was inefficient to eradicate biofilms while the matrix was not a shield to the antibiotic diffusion and to 28 its interaction with its bacterial target. In the presence of rifampicin, daptomycin was still present in the 29 vicinity of the bacterial cells allowing the prevention of the emergence of rifampicin-resistant mutants. 30
Conclusions derived from this study strongly suggest that S. aureus biofilms resistance/tolerance 31 towards daptomycin may be more likely related to a physiological change involving structural 32 modifications of the membrane, which is a strain-dependent process. 33
INTRODUCTION 35
Staphylococcus aureus (S. aureus) is a Gram-positive bacteria shown to be the most frequent 36 cause of biofilm-associated infections (BAI) (1) and one of the major cause of morbidity and mortality 37 in hospitals and communities (2). Unlike planktonic cells, biofilms exhibit specific phenotypic traits 38 allowing them to resist host defenses and antibiotic treatments (3), which frequently leads to chronic 39
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To assess antibiotics activities, the 24 h-biofilms were rinsed with a 150 mM NaCl aqueous solution 105 before adding the antibiotics solutions diluted in TSBpc as described previously. Viable culturable 106 bacteria were then counted at regular interval times: 0 h (when antibiotics are added), 24, 48 and 72 h 107 after antibiotics injection. For each time, bacterial cultures were centrifuged 10 min at 7000g in order to 108 eliminate the excess of antibiotic. The bacterial pellet was dispersed in NaCl 150 mM sterile saline 109 solution, centrifuged again and dispersed in the same conditions. Successive decimal dilutions were 110 then realized. For each dilution, six drops (10 µL) were deposited on Tryptic Soy Agar (TSA) plates 111 (Biomérieux, France) and incubated at 37°C during 24 h. CFUs were counted and averaged for each 112 dilution at each time. The detection limit of viable culturable cells was 100 CFU/mL. 113
Percentage of rifampicin-resistant mutants in biofilms 114
To measure percentages of rifampicin-resistant mutants, the antibiotics solutions (rifampicin combined 115 or not with daptomycin) were added to 24 h-biofilms. CFUs were counted on TSA plates containing or 116 not rifampicin (20 µg/mL) at 24 and 48 h after antibiotics injections. The percentages were obtained by 117 calculating the ratio between the number of CFUs grown on rifampicin-containing TSA plates and the 118 number of CFUs grown on rifampicin-free TSA plates. 119
Statistical analysis 120
The mean log 10 CFU/mL and biovolumes for each therapy were compared with each other using 121 ANOVA variance analyses. They were performed using the Statgraphics software (Manugistics, 122
Rockville, USA). Significance was defined as a P-value associated with a Fisher test value lower than 123 0.05. 124
Confocal Laser Scanning Microscopy (CLSM) 125
Visualization of antibiotics activities against biofilms using Live/Dead® staining 126 24 h-biofilms prepared as described previously were observed 24, 48 and 72 h after antibiotics addition 127 using a Leica TCS SP5 confocal laser scanning microscope (Leica Microsystems, France) implemented were reconstructed in 3D using ICY® Software. 137
Quantification of biovolumes and maximum thickness 138
Maximum thickness (µm) was measured directly from xyz stacks. Biovolumes (µm 3 ) were calculated 139 by binarizing images with a java script executed by ICY as described previously (21). The biovolume 140 was then defined as the overall volume of cells in the observation field. The percentage of dead cells 141 corresponds to the ratio between biovolumes of PI-stained bacteria and Syto9®-stained bacteria. 142
Antibiotics penetration and localization inside biofilms 143
To study the penetration of BODIPY®-FL-daptomycin and its combination with rifampicin within 144 24 h-biofilms, we employed time-lapse microscopy, as described before (22), using the same Leica 145 TCS SP5 confocal microscope. Briefly, the fluorescence intensity evolution over time was observed in 146 a defined focal plane (5 µm above the substratum surface). As soon as the TSBpc-diluted solutions of 147 BODIPY-FL®-daptomycin combined or not with rifampicin were added above the biofilm, 148 fluorescence intensity images were acquired every second during 15 min. Simultaneously, transmission 149 images were acquired to ensure that no structural alteration of the biofilm occurred during this process. 150
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The labelled antibiotic was excited with a continuous argon laser line at 488 nm through a 63x oil 151 immersion objective and the emitted fluorescence was recorded within 500 and 600 nm. 152
The corresponding diffusive penetration coefficients (D p ) through the biofilms were determined 153 according to the relationship previously described by Stewart (23) : 154
where L is the biofilm thickness and t 90 is the time required to attain 90% of the equilibrium staining 156 intensity at the deeper layers of the biofilm. 157
To observe the localization of the fluorescently-labelled daptomycin within biofilms, bacteria were 158 counterstained with the FM4-64 dye (Life Technologies, France): this dye was also excited at 488 nm 159 but its fluorescence emission was collected within the range 640-750 nm. The images (512 x 512 160 pixels) of both fluorophores were simultaneously recorded with a z-step of 1 µm. 161
Antibiotic diffusion and bioavailability inside biofilms using FRAP experiments 162
Image-based Fluorescence Recovery after Photobleaching (FRAP) measurements was used to assess 163 local diffusion and bioavailability of the fluorescently-labelled daptomycin. Briefly, FRAP is based on 164 a brief excitation of fluorescent molecules by a very intense light source in a user-defined region to 165 irreversibly photobleach their fluorescence. Fluorescence recovery is then probed over time at a low 166 light power in the same photobleached region (22, 24). All time-resolved measurements were obtained 167 using the same confocal microscope. The time course of fluorescence intensity recovery was analyzed 168 with mathematical models, giving access to the quantitative mobility of the fluorescent molecules and 169 allowing to determine the diffusion coefficients. For all FRAP experiments, the fluorescence intensity 170 image size was fixed to 512 x 128 pixels with an 80-nm pixel size and recorded using a 12-bit 171 resolution. The line scan rate was fixed to 1400 Hz, corresponding to a total time between frames of ~ 172
Page 9 of 30 of the bleached profile were 0.8 µm and 14 µm, respectively, allowing to neglect diffusion along the 174 axial/vertical axis and thus to consider only two-dimensional diffusion. Each FRAP experiment started 175 with the acquisition of 50 images at 7% of laser maximum intensity (7 µW) followed by a 200-ms 176 single bleached spot at 100% laser intensity. A series of 450 single section images was then collected 177 with the laser power attenuated to its initial value (7% of the bleach intensity). The first image was 178 recorded 365 ms after the beginning of bleaching. 179
180

RESULTS
181
Susceptibility testing 182
The MICs obtained for daptomycin and rifampicin against the four S. aureus strains are presented in 183 Table 1 . All isolates in planktonic conditions were susceptible to daptomycin and rifampicin. 
Spectroscopic characterization of the interaction between rifampicin and daptomycin 188
Neither the photonic absorption properties nor the fluorescence emission spectrum of daptomycin were 189 significantly influenced by the addition of rifampicin (Fig. 1 First, we checked that no bacterial movement occurred during image acquisition by representing 211 kymograms, two-dimensional graphs of fluorescence intensity measured along a line (here a straight 212 line drawn on the full width of the images) for each image of the FRAP series (Fig. 2a) . A typical 213 FRAP curve of BODIPY-FL®-daptomycin in S. aureus biofilms is presented in Fig. 2b . Whatever the 214 bacterial strains or the treatments used (daptomycin alone and in combination with rifampicin), we 215 demonstrated here that the fluorescence recovery was not total after photobleaching: only 20% of 216 BODIPY-FL-®-daptomycin molecules interacted with the environment, meaning that a large excess of 217 molecules (80%) were diffusing freely in the defined-regions and thus bioavailable (mean local 218 diffusion coefficient, 7.1 +/-0.6 µm²/s).
Localization of the fluorescently-labelled daptomycin combined or not with rifampicin depending on 220
the surrounding environment: As daptomycin is known to be highly bound to serum proteins (90-221 93%) (26), we addressed the question of whether there could be a different localization of the 222 fluorescently-labelled daptomycin in a protein-enriched medium. As shown in Fig. 3 , fluorescence 223 intensity images were significantly different depending on the surrounding medium: regardless of the 224 strain tested, the antibiotic appeared to be colocalized with the FM4-64 dye at the bacterial site when 225 the surrounding medium was a NaCl aqueous solution supplemented in calcium while the antibiotic 226 localization appeared to be mainly extracellular when the medium was enriched with proteins (TSBpc). 227
The addition of rifampicin did not affect daptomycin localization in the biofilm. 228
Combining 3D-fluorescence imaging and time-kill studies to assess S. aureus biofilms inactivation 229 in the presence of daptomycin alone and in association with rifampicin 230
We used confocal microscopy to describe the three-dimensional structures of biofilms and the temporal 231 distribution of both live and dead cells throughout the biofilm thickness. 232
Fluorescence intensity images showed that the biofilms formed by the four strains yielded similar 233 compact structures (Fig. 4a and Fig. S2 controls) . Their thicknesses were neither significantly variable 234 from one strain to another (25-29 µm, P > 0.05), nor between 24 h and 72 h. This is a reasonable result 235
given that the culture medium (TSBpc) was renewed before the first observation but not over time: thus 236 biofilm development mainly occurred during the first 24 h. 237
When treated with daptomycin, biofilms exhibited more free-of-cells areas compared with controls 238 (Fig. 4a and Fig. S2 ). This can be related to significant decreases in biofilms thicknesses (19-21 µm in 239 the presence of daptomycin, P < 0.05) by comparison with the control biofilms. Moreover, in the 240 presence of daptomycin, no statistically significant change in the proportion of cell death over time was 241 quantified (10-30 %, P > 0.05) (Fig. 4b) . However, the MRSA clinical isolate (BCB8) was more 242
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By comparison with the monotherapy treatment, the biofilms structures and thicknesses were not 245 affected when they were treated with daptomycin in combination with rifampicin. However, in these 246 conditions, a significantly higher proportion of cell death was observed, achieving 85% at 72 h (P < 247 0.01) (Fig. 4b) . For the two MSSA strains (27217, 176) and the MRSA collection strain (33591), the 248 antibiotics association activity gradually increased over time (Fig. 4) while the maximum activity 249 against the MRSA clinical strain (BCB8) was reached within 24 h. 250
Another observation of interest (Fig. 4a) is that upon daptomycin exposure, dead cells were observed 251 over the whole biofilm depth, including the basal layer of cells in contact with the substratum, 252 providing further evidence of the antibiotic penetration throughout the deepest layers of the biofilms. 253
This result is even more observable for the BCB8 strain because of the greater proportion of dead cells 254 involved by the action of daptomycin. This process was also observed when daptomycin was used in 255 association with rifampicin. 256
These data from fluorescence imaging were supported by CFU counts of suspended biofilms (Fig. 5) . 257
The results confirm that daptomycin alone was ineffective against biofilms formed by the two MSSA 258 strains (27217, 176) and the MRSA collection strain (33591). For the MRSA clinical isolate (BCB8), 259 only ~1-2-log reduction in bacterial counts was measured at 24 h before regrowth was observed to 260 reach the same values as for the MSSA biofilms. 261
In accordance with fluorescence imaging data, the activity of the antibiotics combination was much 262 greater than the monotherapy. The sensitivity of the microbiological method allowed determining that 263 the cell population decreased by ~ 4 log after 72 h of treatment (P < 0.05). The emergence of 264
Page 13 of 30 rifampicin-resistant mutants was verified. As presented in Fig. 6 , daptomycin dramatically prevented 265 the emergence of rifampicin-resistant mutants when used in combination. 266
267
DISCUSSION 268
The choice of antibiotics to treat S. aureus BAI remains a challenge for the medical community. 269
In this context, the ambivalence of the published results on daptomycin activity is a relevant example. 270
Despite increasing data about daptomycin as an option to treat implant-associated S. aureus infections, 271 as many failures (18, 27) as successes (7-9, 12) have been reported both in clinical practice and in 272 laboratory models. This highlights that S. aureus BAI resistance/tolerance mechanisms to 273 antimicrobials deserve more attention. 274
The biofilm-associated exopolymeric matrix may be considered to act as a shield to the 275 antimicrobial diffusion-reaction (28-32) by delaying its penetration and/or reducing its bioavailability. antibiotic was distributed majorly in the extracellular matrix rather than in the bacterial cell membranes 290 (Fig. 3) . This is in agreement with the well-known property of daptomycin to have a very high degree 291 of protein-binding, especially with serum albumin (90-93%) (26, 33) which is naturally present in 292 physiological conditions. Nevertheless, the fluorescence recovery curves obtained by FRAP 293 experiments in free medium and in the biofilms strongly suggested the reversibility of daptomycin 294 protein-binding (33, 34): the equilibrium between the bound and unbound states may conserve the 295 apparent mobility of the antibiotic. Additional experiments were performed in a protein-free medium (a 296 saline solution supplemented with calcium ions). In this case, bacterial cell membranes appeared as hot 297 spots on fluorescence images, consistently with the described antibiotic interaction with its target (6). 298 Surprisingly, whether the medium was protein-free or not, daptomycin exhibited the same lack of 299 effectiveness, as revealed by time-kill studies performed by fluorescent live-dead staining and 300 conventional plating on agar (data not shown in the absence of proteins). Thus, the interaction with the 301 matrix components cannot explain biofilm tolerance to the antibiotic. 302
The particular physiology of embedded bacteria should be thus considered and more 303 specifically cells with a low metabolic activity. Previous studies using a BrdU immunofluorescent 304 labelling technique demonstrated that the large majority of staphylococci cells in a biofilm were 305 actually in a low-metabolic state (35, 36). Additionally, in the present study, the comparison of cell 306 viability results obtained by CFU counts and fluorescence imaging highlighted a significant proportion 307 of viable cells detected by Live-Dead® staining but not by CFU measurements. This subpopulation 308 may be considered as viable but non-culturable (VBNC), a subpopulation known to have a slow 309 metabolism (37-39). Moreover, it has been demonstrated that daptomycin is poorly effective against 310 bacteria in stationary stage (7, 27). One can thus reasonably suggest that for bacteria with low 
